Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo
about
Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expressionWounds that will not heal: pervasive cellular reprogramming in cancerThe solution structure of the N-terminal domain of human vitronectin: proximal sites that regulate fibrinolysis and cell migrationRandom peptide bacteriophage display as a probe for urokinase receptor ligands.Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migrationProbing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.Coordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells.Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.Integrin α3β1 as a breast cancer targetRNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding.Compensatory redistribution of neuroligins and N-cadherin following deletion of synaptic β1-integrin.Antiprotease therapy in cancer: hot or not?Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.Differential expression profiling of head and neck squamous cell carcinoma (HNSCC).Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression.Simultaneous downregulation of uPAR and MMP-9 induces overexpression of the FADD-associated protein RIP and activates caspase 9-mediated apoptosis in gliomas.Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61Urokinase plasminogen activator system as a potential target for cancer therapy.Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.Involvement of urokinase-type plasminogen activator system in cancer: an overview.Effect of His-Gly-Lys motif derived from domain 5 of high molecular weight kininogen on suppression of cancer metastasis both in vitro and in vivo.The N terminus of mannose 6-phosphate/insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration.Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells.The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in miceA convenient clinically relevant model of human breast cancer bone metastasis.Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor.Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.Expression of the urokinase receptor regulates focal adhesion assembly and cell migration in adenoid cystic carcinoma cells.Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells.The receptor for urokinase-type plasminogen activator regulates fibronectin matrix assembly in human skin fibroblasts.The cleavage of the urokinase receptor regulates its multiple functions.Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients.Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.A dual role for caveolin-1 in the regulation of fibronectin matrix assembly by uPAR.Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease.The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V{beta}3 integrins.Urokinase-type plasminogen activator receptor regulates a novel pathway of fibronectin matrix assembly requiring Src-dependent transactivation of epidermal growth factor receptor.
P2860
Q25257709-AC981B83-84DE-4B65-98F3-ECD0CAAE2421Q26828560-FE510944-62D5-4CBA-85E6-C924A8A6299BQ28259956-0843CF7E-87DE-4233-940A-25C014EA2D22Q31047145-8F0A7726-027E-41E3-B0A7-1AC039E2F9E2Q33587120-5313DC83-7F44-401B-A381-D1EA0DA3BC7DQ33758094-68795E6A-A7EE-49EB-ABC3-52D357D3673DQ33812093-E89D8E25-1691-4E06-8C6B-CBA0276D398CQ34567465-36D48527-A6C8-454C-9C57-2A5DE525F087Q35219000-1193A0F6-E985-4B0B-98DB-C7A6229F9095Q35539262-EDE5128C-6E48-4BDF-B410-F31B9D312913Q35920401-3EECE729-E963-4FC8-BC88-A6F861550346Q36321377-EF24AC39-D2F9-4022-9ECE-7A0FCF99A87BQ36393924-B22546D5-DF22-4E53-9B16-DC2C724EEB2CQ36407244-84FACA85-ACE6-4085-9D64-FB3E626AD07EQ36616741-F27AB2C4-03B7-457F-BED4-784D13AEFDEFQ36671602-03DFD22A-FF9A-491E-B239-DDF0C5AEDDEBQ36673754-1F0A1787-AD94-43AB-A0B0-6F9E16D896DEQ36925536-9B772C4D-9D29-4796-8E37-F29CD83770A4Q37255447-CD97FFB1-5BEC-417B-9FFD-939E3C9D5215Q37630593-851B0D0E-7E75-456E-8AE3-1CAF661A6D08Q37895294-227D4D61-6EE7-4D0F-B8A3-57C0C244BA7CQ38189275-3696645D-97F6-41F0-8397-0504634D664DQ38350114-15AAD316-DF0D-4ED2-973D-39B259998187Q38363599-A700C876-724D-45AB-93CE-35216A319189Q38601915-3D8FEDB0-6243-4FA1-B7DE-4989D5C0367FQ39842498-14770291-8E64-4EFB-8419-83A4828E05E8Q40074885-8503CACE-7D51-44EC-B5DB-CDDEA01E65AEQ40240628-CF44EDAD-46A9-440A-B45C-A58AFB554F14Q40486051-867ACE35-6008-4FCE-9C0E-0CC1315DA09CQ40496993-F52A1571-D89A-45CA-BA07-F877294E86ADQ40612563-206DDC9B-1B51-4C6E-9D56-62DF57B8ED02Q40619209-FFF7CF68-0EED-4F2D-8015-5B8D8D432128Q40701611-0BC659DD-ABCA-4AC9-8F5E-1E0D371FEEBBQ41469380-5A0F7F53-DD55-4D7C-AB44-23626174092AQ41518094-0D9BFA1B-A18F-439F-BDE8-95FBA35EEA3CQ41934121-73F2E030-BEF5-4CC6-B577-3B3B36FC078BQ46260348-100516F7-7F4C-4077-9DAB-97B5405B8621Q46610587-DD3767F0-19DB-426C-8C1A-28A1645414EDQ46930699-D5528168-6942-4F53-AB47-0F1FA0A1F8EE
P2860
Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Urokinase-receptor/integrin co ...... of human breast cancer in vivo
@ast
Urokinase-receptor/integrin co ...... of human breast cancer in vivo
@en
Urokinase-receptor/integrin co ...... of human breast cancer in vivo
@nl
type
label
Urokinase-receptor/integrin co ...... of human breast cancer in vivo
@ast
Urokinase-receptor/integrin co ...... of human breast cancer in vivo
@en
Urokinase-receptor/integrin co ...... of human breast cancer in vivo
@nl
prefLabel
Urokinase-receptor/integrin co ...... of human breast cancer in vivo
@ast
Urokinase-receptor/integrin co ...... of human breast cancer in vivo
@en
Urokinase-receptor/integrin co ...... of human breast cancer in vivo
@nl
P2093
P2860
P1476
Urokinase-receptor/integrin co ...... of human breast cancer in vivo
@en
P2093
C van der Bent
G van der Pluijm
H Vloedgraven
J Verheijen
J W Drijfhout
M Karperien
S Papapoulos
P2860
P304
P356
10.1016/S0002-9440(10)61773-7
P407
P50
P577
2001-09-01T00:00:00Z